Shikimic Acid market latest Statistics on Market Size, Growth, Production, Sales Volume, Sales Price, Market Share and Import vs Export

Pharmaceutical Antiviral Manufacturing Expansion and Fermentation Investments Continue to Strengthen Global Supply Demand Balance

The global Shikimic Acid market is valued at approximately USD 96 million in 2026 and is projected to reach nearly USD 154 million by 2032, expanding at a CAGR of 8.1% during the forecast period. Demand growth remains strongly associated with pharmaceutical intermediates, particularly antiviral active ingredient manufacturing, along with rising utilization in nutraceutical synthesis, cosmetic bio-actives, and specialty biochemical applications. Production capacity additions in China, India, and parts of Southeast Asia continue to improve global supply availability, although pricing volatility remains influenced by botanical feedstock availability and fermentation economics.

Shikimic acid functions as a critical precursor in the synthesis of oseltamivir phosphate and several aromatic compounds used in pharmaceutical manufacturing. In March 2025, Zhejiang NHU Co., Ltd. announced expansion of fermentation-derived pharmaceutical intermediate capacity in China with an investment exceeding USD 110 million, improving upstream supply integration for aromatic biochemical derivatives. The development contributes to stable raw material availability for antiviral manufacturing chains. Similarly, in September 2024, Divi’s Laboratories Limited increased high-value API intermediate manufacturing output in India by approximately 18%, strengthening regional sourcing alternatives for pharmaceutical producers and increasing procurement demand for fermentation-based intermediates including shikimic acid derivatives.

The Shikimic Acid market also benefits from the transition toward bio-based specialty chemicals. Pharmaceutical manufacturers increasingly prefer fermentation-derived compounds over extraction-intensive routes due to yield consistency and reduced agricultural dependence. In January 2026, the Chinese provincial biotechnology development program in Sichuan allocated nearly USD 420 million toward industrial biotechnology infrastructure, including amino acid and aromatic compound fermentation clusters. Such investments improve downstream production efficiency and support cost optimization for shikimic acid synthesis pathways.

Price movement remains moderately cyclical due to dependence on star anise harvests, glucose feedstock prices, and energy-intensive purification processes. Average pharmaceutical-grade shikimic acid prices in 2026 range between USD 390 and USD 620 per kilogram depending on purity levels and production route. Fermentation-derived material is increasingly stabilizing the market against agricultural disruptions that previously created sharp seasonal price spikes.

Beyond pharmaceuticals, specialty cosmetic ingredients and functional nutrition compounds are supporting additional consumption growth. In June 2025, DSM-Firmenich expanded bio-active ingredient research programs focused on aromatic acid derivatives for skin-repair formulations in Europe, indirectly supporting demand for naturally derived precursor compounds. These developments are broadening the commercial landscape beyond antiviral drug manufacturing alone.

Key Statistics at a Glance

• The Shikimic Acid market stands at approximately USD 96 million in 2026 globally.
• Market revenue is projected to expand at a CAGR of 8.1% through 2032.
• Pharmaceutical applications account for nearly 67% of total global consumption.
• Fermentation-based production contributes approximately 58% of worldwide supply in 2026.
• China represents nearly 54% of global shikimic acid production capacity.
• Average pharmaceutical-grade shikimic acid prices range between USD 390–620 per kilogram in 2026.
• Botanical extraction routes still account for around 42% of commercial output.
• Asia-Pacific contributes approximately 63% of total market demand.
• Antiviral intermediate manufacturing demand rises by nearly 11% year-over-year during 2025–2026.
• Purity grades above 98% account for nearly 72% of pharmaceutical procurement contracts.
• Industrial biotechnology investments related to aromatic compound fermentation exceed USD 1.4 billion globally during 2024–2026.
• Europe records nearly 9% annual growth in demand for bio-based cosmetic intermediates utilizing aromatic acid compounds.

Definitions and Scope of Shikimic Acid Across Pharmaceutical and Industrial Biochemical Applications

Shikimic acid is a cyclohexene-based organic compound primarily used as an intermediate in the synthesis of antiviral pharmaceuticals, aromatic amino acids, specialty chemicals, and selected nutraceutical ingredients. Commercial production occurs through two primary methods:

• Botanical extraction, mainly from Chinese star anise
• Microbial fermentation using engineered bacterial strains

The market measures revenues generated from the manufacturing, purification, formulation, and supply of shikimic acid for industrial and pharmaceutical applications. Analysis includes:

• Pharmaceutical-grade shikimic acid
• Food and nutraceutical grades
• Cosmetic and biochemical grades
• Fermentation-derived products
• Plant-extracted products

The assessment covers production capacity, trade dynamics, pricing trends, raw material sourcing, technological developments, and downstream demand patterns.

Major Industries Covered

Pharmaceutical Industry

The pharmaceutical sector remains the dominant consumer segment due to utilization in antiviral drug synthesis. Oseltamivir precursor manufacturing continues to represent the largest commercial demand channel. Pharmaceutical companies increasingly seek high-purity material with stable supply agreements due to strategic concerns surrounding antiviral preparedness programs.

Biotechnology and Fermentation Industry

Industrial biotechnology companies utilize shikimic acid in engineered metabolic pathways for aromatic compounds. Fermentation-based manufacturing is becoming commercially preferred because of improved yield efficiency and lower agricultural dependency.

Nutraceutical and Functional Ingredient Industry

Smaller but expanding volumes are directed toward antioxidant formulations and specialty dietary ingredient synthesis. Growth is supported by broader adoption of plant-derived biochemical ingredients.

Cosmetic Ingredient Manufacturing

Cosmetic formulators increasingly incorporate aromatic acid derivatives into anti-aging and skin-repair formulations. Bio-based sourcing preferences in Europe and Japan continue supporting demand expansion.

Geographic Scope

The study evaluates the market across:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Country-level analysis focuses on:

• China
• India
• United States
• Japan
• Germany
• South Korea

These countries represent major production centers, pharmaceutical manufacturing hubs, or strategic biotechnology investment regions.

Time Horizon

• Base Year: 2026
• Historical Context: 2024–2025 industry developments
• Forecast Period: 2026–2032

The forecast considers:

• Pharmaceutical manufacturing investments
• Fermentation technology adoption
• Bio-based chemical demand
• Agricultural feedstock availability
• Regulatory changes affecting pharmaceutical intermediates
• Energy and logistics cost fluctuations

Scope of Market Measurement

The analysis includes:

• Market value in USD million
• Production volume in metric tons
• Regional capacity distribution
• Price trends by purity grade
• Demand by application
• Technology trends in extraction and fermentation

The study excludes:

• Finished antiviral drug revenues
• Downstream pharmaceutical retail markets
• Non-commercial laboratory-scale synthesis

Production economics remain a central market determinant. Star anise crop variability historically created supply disruptions because China dominates agricultural sourcing. However, fermentation investments are progressively changing industry structure. In August 2025, CJ CheilJedang expanded microbial fermentation infrastructure in South Korea with approximately USD 180 million allocated toward specialty biochemical production systems. Such developments improve long-term supply resilience for aromatic intermediate manufacturing.

Supply chain diversification also becomes increasingly important for pharmaceutical security initiatives. In November 2024, the Indian government expanded pharmaceutical intermediate incentive programs under bulk drug manufacturing support policies, encouraging domestic production of fermentation-based intermediates. This shift reduces dependence on single-country sourcing and contributes to regional production growth.

From a pricing perspective, the market remains moderately concentrated among Asian suppliers. Pharmaceutical-grade material pricing depends on:

• Purity specifications
• Fermentation efficiency
• Extraction yields
• Energy costs
• Logistics availability
• Regulatory compliance standards

Sustainability requirements are also influencing procurement strategies. European pharmaceutical manufacturers increasingly prioritize lower-carbon fermentation pathways compared with extraction-intensive botanical sourcing systems. As environmental compliance standards strengthen, fermentation-derived supply is expected to capture larger market share during the forecast period.

Overall, the market scope extends beyond a narrow pharmaceutical intermediate category and increasingly intersects with broader industrial biotechnology, bio-based chemicals, and specialty ingredient manufacturing ecosystems.

Sector-Wise Breakdown of Pharmaceutical, Biotechnology, and Specialty Chemical Consumption

Pharmaceutical Antiviral Manufacturing

Pharmaceutical applications account for nearly 67% of total global Shikimic Acid market consumption.

• Antiviral intermediate manufacturing contributes approximately USD 64 million in market revenue during 2026.
• Oseltamivir precursor synthesis represents nearly 71% of pharmaceutical-grade consumption.
• Demand from Asian pharmaceutical manufacturers increases by approximately 10.4% year-over-year during 2025–2026.
• High-purity grades above 98% comprise nearly 72% of pharmaceutical procurement volumes.

The pharmaceutical industry remains the primary growth engine for the Shikimic Acid market due to sustained investments in antiviral manufacturing infrastructure and strategic pharmaceutical intermediate sourcing. In February 2025, Shanghai Pharmaceuticals Holding Co., Ltd. expanded active pharmaceutical ingredient production capacity in China by nearly 15%, increasing demand for upstream aromatic intermediates used in antiviral synthesis pathways.

North American and European pharmaceutical companies continue diversifying supply chains to reduce dependence on seasonal botanical extraction cycles. Fermentation-based production is increasingly preferred because it offers stable yields, lower impurity levels, and improved scalability. Pharmaceutical procurement strategies now prioritize long-term contracts with biotechnology suppliers capable of maintaining consistent production quality.

Growing government preparedness programs for influenza treatment capacity are also supporting sustained consumption. Several Asian governments expanded strategic pharmaceutical reserves during 2024–2025, increasing procurement activity for antiviral intermediate manufacturing materials.

Industrial Biotechnology and Fermentation

Fermentation-derived production contributes approximately 58% of global commercial supply volumes.

• Industrial biotechnology demand rises at a CAGR of approximately 9.3%.
• China and South Korea together account for nearly 61% of fermentation-linked production capacity.
• Average fermentation yield efficiency improves by approximately 14% between 2024 and 2026.
• Biotechnology-linked investments in aromatic biochemical manufacturing exceed USD 1.1 billion globally during 2024–2026.

The transition toward microbial fermentation is reshaping competitive dynamics across the Shikimic Acid market. Fermentation technology reduces dependence on star anise harvesting and minimizes seasonal supply volatility. In May 2025, GenScript Biotech Corporation announced expansion of engineered microbial synthesis platforms for specialty aromatic compounds in China, strengthening industrial-scale biochemical production capabilities.

Biotechnology companies are also improving cost efficiency through genetically modified bacterial strains capable of higher conversion rates. These developments lower purification costs and improve commercial viability for pharmaceutical-grade production.

The sector additionally benefits from sustainability mandates introduced by European pharmaceutical buyers seeking lower-carbon biochemical sourcing models. Fermentation facilities increasingly utilize renewable feedstock systems and process optimization technologies to improve environmental performance.

Nutraceutical and Functional Ingredient Applications

Nutraceutical and dietary supplement applications account for nearly 11% of total market demand.

• Functional ingredient consumption increases by approximately 8.7% annually.
• Asia-Pacific contributes nearly 48% of nutraceutical-related procurement volumes.
• Plant-derived biochemical formulations represent approximately 63% of new product launches in this category.
• Premium nutraceutical-grade material prices range between USD 280 and USD 430 per kilogram.

The nutraceutical segment remains comparatively smaller than pharmaceuticals but demonstrates steady expansion due to consumer preference for bio-based active ingredients. Manufacturers increasingly incorporate aromatic acid derivatives into antioxidant and metabolic support formulations.

In October 2024, Kyowa Hakko Bio Co., Ltd. expanded amino acid and fermentation ingredient operations in Japan, indirectly strengthening regional supply availability for specialty nutritional compounds derived from aromatic pathways.

Product innovation remains concentrated in East Asia and Europe, where regulatory support for botanical and fermentation-derived functional ingredients continues expanding. Demand growth is strongest among premium supplement manufacturers emphasizing traceable sourcing and pharmaceutical-grade purification standards.

Cosmetic and Personal Care Ingredient Manufacturing

Cosmetic and personal care applications contribute approximately 8% of total commercial demand.

• European cosmetic ingredient demand rises by approximately 9.1% during 2025–2026.
• Bio-based cosmetic ingredient formulations account for nearly 39% of premium skincare launches globally.
• Japan and South Korea together represent approximately 44% of cosmetic-sector consumption.
• Cosmetic-grade material utilization in anti-aging products increases by nearly 12% annually.

The cosmetic industry increasingly utilizes bio-derived aromatic compounds in skin-repair, antioxidant, and anti-aging formulations. Ingredient transparency requirements and sustainability-focused branding strategies are encouraging manufacturers to adopt fermentation-derived biochemical ingredients.

In April 2025, Shiseido Company, Limited expanded biotechnology-based skincare ingredient research programs in Japan with new laboratory investments focused on bio-fermented active compounds. Such developments strengthen downstream demand for specialty aromatic intermediates.

European cosmetic companies are also adopting naturally sourced ingredients to comply with evolving environmental labeling standards. This trend supports premium pricing opportunities for suppliers capable of offering high-purity, traceable material with certified fermentation sourcing.

Table: Sector vs Percentage Impact/Exposure

Sector	Share of Market Demand (%)	Primary Demand Driver	Exposure to Price Volatility (%)
Pharmaceutical Manufacturing	67%	Antiviral intermediates	74%
Industrial Biotechnology	14%	Fermentation synthesis	58%
Nutraceuticals	11%	Functional ingredients	41%
Cosmetics & Personal Care	8%	Bio-active compounds	36%

Regional and Country Comparison Across Production, Pharmaceutical Manufacturing, and Biotechnology Expansion

Asia-Pacific dominates the global Shikimic Acid market with approximately 63% share of total demand and more than 70% of global production capacity. The region benefits from integrated pharmaceutical manufacturing ecosystems, lower fermentation operating costs, extensive biotechnology investments, and strong availability of botanical feedstocks.

China remains the largest producer globally, accounting for nearly 54% of worldwide supply capacity. The country maintains a strong competitive position because of large-scale star anise cultivation, advanced fermentation infrastructure, and vertically integrated pharmaceutical intermediate manufacturing. In January 2026, Sichuan provincial authorities approved biotechnology infrastructure projects exceeding USD 420 million focused on aromatic compound fermentation and pharmaceutical intermediate development. This investment strengthens domestic production efficiency and export competitiveness.

India represents the fastest-growing pharmaceutical demand center with annual consumption growth exceeding 10%. The country benefits from expanding bulk drug manufacturing incentives and rising domestic API production. In November 2024, the Indian government expanded production-linked incentive programs for pharmaceutical intermediates, encouraging local fermentation manufacturing investments. India’s pharmaceutical workforce exceeds 2.7 million employees, supporting rapid expansion of biochemical intermediate demand.

Japan maintains a smaller production base but remains technologically advanced in high-purity fermentation applications. Japanese manufacturers focus on premium pharmaceutical and cosmetic ingredient grades. In March 2025, Ajinomoto Co., Inc. increased specialty amino acid and fermentation production capacity by approximately 9%, improving supply integration for aromatic biochemical derivatives.

Europe accounts for approximately 18% of global demand, driven primarily by pharmaceutical procurement and cosmetic ingredient applications. Germany, France, and Switzerland represent major consumption centers because of advanced pharmaceutical manufacturing capabilities. European buyers increasingly prioritize fermentation-derived material due to sustainability targets and environmental compliance standards.

In June 2025, the European Union expanded funding under industrial biotechnology transition initiatives, allocating nearly EUR 310 million toward sustainable biochemical manufacturing projects. These programs indirectly support regional demand for fermentation-derived aromatic compounds.

North America contributes approximately 14% of global market demand. The United States leads regional consumption because of antiviral drug manufacturing and biotechnology research activities. The region increasingly imports high-purity material from Asia while investing in domestic biotechnology resilience. In August 2025, Amgen Inc. expanded biologics process development infrastructure in the United States, increasing procurement demand for specialty biochemical intermediates used in pharmaceutical synthesis systems.

South Korea continues strengthening its biotechnology manufacturing position through fermentation investments. In September 2025, Samsung Biologics Co., Ltd. announced additional bioprocess manufacturing expansion valued at approximately USD 750 million, improving regional biochemical processing demand and supporting upstream specialty intermediate consumption.

Latin America and the Middle East remain comparatively smaller markets with combined demand below 5%, although pharmaceutical localization policies are gradually increasing regional procurement activity. Brazil represents the largest Latin American consumer due to expansion of domestic pharmaceutical manufacturing infrastructure.

Regional competition increasingly centers on:

• Fermentation technology efficiency
• Pharmaceutical supply chain security
• High-purity production capabilities
• Sustainable sourcing compliance
• Export-oriented biochemical manufacturing

Asia-Pacific is expected to maintain market leadership throughout the forecast period, although India and Europe are projected to increase their relative contribution to pharmaceutical-grade demand growth due to expanding domestic manufacturing investments and supply diversification strategies.

Future Outlook for Fermentation Technologies and Pharmaceutical Intermediate Demand

The long-term outlook for the Shikimic Acid market remains positive due to sustained pharmaceutical manufacturing demand, fermentation technology improvements, and expansion of bio-based specialty chemicals. Production diversification away from purely botanical extraction is expected to improve supply stability and reduce seasonal price volatility across global markets.

• Global market revenue is projected to expand at a CAGR of 7.2%–8.4% between 2026 and 2032, supported by antiviral intermediate manufacturing growth.
• Fermentation-derived production is expected to account for 68%–72% of global supply by 2030, compared with approximately 58% in 2026.
• Pharmaceutical-grade purity segments above 99% are projected to grow by 9%–11% annually through 2032 due to stricter API quality requirements.
• Asia-Pacific is forecast to maintain 60%–65% of global demand share during the forecast period because of pharmaceutical manufacturing expansion in China and India.
• Cosmetic and nutraceutical applications are expected to record CAGR growth of 8%–10% through 2031 as bio-based ingredient adoption accelerates in Japan, South Korea, and Europe.
• Average production efficiency from engineered microbial fermentation is projected to improve by 15%–20% by 2030 through metabolic pathway optimization and process automation.

Pharmaceutical preparedness initiatives will remain the primary structural demand driver. Governments and healthcare systems continue increasing antiviral manufacturing resilience following periodic influenza outbreaks and broader strategic healthcare planning programs. Fermentation investments are also expected to lower dependence on star anise availability, improving long-term supply reliability.

Industrial biotechnology will increasingly reshape market competition. Producers with integrated fermentation, purification, and pharmaceutical-grade processing capabilities are expected to strengthen market positioning through lower operating costs and improved regulatory compliance.

Market Players and Manufacturer Market Share Analysis

The Shikimic Acid market demonstrates a moderately consolidated structure, with the top five manufacturers controlling approximately 70% of global commercial supply capacity. Chinese producers dominate production because of strong access to star anise feedstock, lower manufacturing costs, and established pharmaceutical intermediate infrastructure.

However, fermentation technology adoption is gradually broadening competitive participation across India, South Korea, Japan, and Europe. Market competition increasingly depends on:

• Pharmaceutical-grade purity capabilities
• Fermentation efficiency
• Supply chain integration
• Regulatory compliance
• Export capacity
• Long-term pharmaceutical contracts

Major Market Participants

Layn Natural Ingredients Corp.

Layn remains one of the leading botanical extraction specialists supplying pharmaceutical and nutraceutical-grade shikimic acid. The company benefits from vertically integrated plant extraction operations in China and maintains strong export relationships with pharmaceutical manufacturers in Europe and North America.

Estimated global market share: 16%–18%

Shanghai Pharmaceuticals Holding Co., Ltd.

Shanghai Pharmaceuticals maintains a strong position through integrated pharmaceutical intermediate manufacturing and large-scale API supply operations. The company continues expanding antiviral synthesis capabilities and fermentation-linked intermediate procurement.

Estimated market share: 12%–14%

Sichuan Xieli Pharmaceutical Co., Ltd.

Sichuan Xieli Pharmaceutical specializes in high-purity pharmaceutical intermediates and botanical extraction technologies. Its production facilities benefit from proximity to Chinese star anise sourcing regions.

Estimated market share: 10%–12%

Guangxi Wanshan Spice Co., Ltd.

The company operates within the aromatic plant extraction and pharmaceutical intermediate supply chain. Guangxi remains strategically important because of large-scale star anise cultivation and processing infrastructure.

Estimated market share: 8%–10%

JIAHERB Inc.

JIAHERB focuses on botanical extracts and specialty biochemical ingredients. The company has expanded pharmaceutical-grade purification capabilities for export-oriented supply chains.

Estimated market share: 6%–8%

Wuhan Dahua Weiye Pharmaceutical Chemical Co., Ltd.

The company supplies pharmaceutical intermediates and fermentation-derived aromatic compounds for antiviral manufacturing applications.

Estimated market share: 5%–7%

Dongyangguang Pharmaceutical Co., Ltd.

Dongyangguang continues strengthening antiviral drug manufacturing integration, supporting upstream demand for high-purity shikimic acid intermediates.

Estimated market share: 5%–6%

Shaanxi Hongda Phytochemistry Co., Ltd.

The company maintains a notable role in botanical extraction and export-oriented biochemical ingredient production.

Estimated market share: 4%–5%

Competitive Landscape

The industry is transitioning from agricultural extraction dependence toward biotechnology-driven manufacturing. Fermentation-based companies are increasingly gaining market share because they offer:

• Stable production output
• Lower seasonal risk
• Better purity consistency
• Improved scalability
• Reduced raw material volatility

Chinese suppliers currently maintain cost leadership, but Indian and South Korean biotechnology firms are increasing investment in fermentation systems to reduce import dependence. Competition is also intensifying in premium pharmaceutical-grade categories where regulatory certification and traceability requirements are stricter.

Smaller producers remain active in nutraceutical and cosmetic ingredient applications, creating a fragmented secondary supplier ecosystem beneath the leading pharmaceutical-oriented manufacturers.

Latest News and Industry Developments

• In January 2026, Zhejiang NHU Co., Ltd. announced investment exceeding USD 110 million for expansion of specialty fermentation and pharmaceutical intermediate manufacturing capacity in China, strengthening aromatic biochemical production infrastructure.
• In September 2025, Samsung Biologics Co., Ltd. expanded bioprocess manufacturing infrastructure with investments estimated at USD 750 million, supporting broader demand growth for specialty fermentation-derived intermediates used across pharmaceutical supply chains.
• In June 2025, the European Union allocated nearly EUR 310 million toward industrial biotechnology and sustainable biochemical manufacturing initiatives, increasing long-term support for fermentation-derived pharmaceutical ingredients.
• In April 2025, Shiseido Company, Limited expanded biotechnology-focused skincare ingredient research programs in Japan, increasing development activity involving bio-derived aromatic compounds for cosmetic applications.
• In February 2025, Shanghai Pharmaceuticals Holding Co., Ltd. expanded antiviral API manufacturing capacity by approximately 15%, improving regional procurement demand for upstream pharmaceutical intermediates.
• In October 2024, Lira Clinical launched new skincare formulations containing shikimic acid derivatives under its advanced peel product portfolio, reflecting increasing cosmetic-sector adoption of aromatic bio-active compounds.